Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.31 |
| ▸ | GCGR | P47871 | 2/20 | 0.31 |
| ▸ | GIPR | P48546 | 2/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30767590 | 1.00 | GRM2 (0.32) | GRM2EDNRBEDNRACHRM5GCGR | |
| SCHEMBL30767451 | 1.00 | GRM2 (0.32) | GRM2EDNRBEDNRACHRM5GCGR | |
| SCHEMBL30767410 | 0.93 | GRM2 (0.34) | GRM2EDNRBEDNRACHRM5GCGR | |
| SCHEMBL31665008 | 0.90 | GRM2 (0.33) | GRM2CHRM5GCGRGIPRHCRTR1 | |
| SCHEMBL30767361 | 0.87 | HCRTR1 (0.34) | GRM2EDNRBEDNRACHRM5HCRTR1 | |
| SCHEMBL30767601 | 0.87 | HCRTR1 (0.34) | GRM2EDNRBEDNRACHRM5HCRTR1 | |
| SCHEMBL30767307 | 0.87 | HCRTR1 (0.34) | GRM2EDNRBEDNRACHRM5HCRTR1 | |
| SCHEMBL30767440 | 0.86 | GRM2 (0.34) | GRM2CHRM5GCGRGIPR | |
| SCHEMBL30767521 | 0.86 | GRM2 (0.34) | GRM2CHRM5GCGRGIPR | |
| SCHEMBL30767589 | 0.85 | MAPT (0.33) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568960-B1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-20250236614-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4568960-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024033458-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236614-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | GRIN2C, CNR1, CNR2 | GRM2 283/4885EDNRB 404/4885EDNRA 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.